01 / Research review
Behind the synopsis.
An original review of the published evidence for PT-141 / Bremelanotide, with human findings separated from laboratory and animal research.
What the compound is
PT-141 is the development name associated with bremelanotide, a melanocortin-receptor agonist. Early research explored erectile responses, while the pivotal later programme focused on acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women. These are different clinical questions and populations. [4][5]
Study design / population & endpoints
Who was studied, and what was measured?
The RECONNECT findings answer a specific clinical question.
Population
Premenopausal women with acquired, generalised hypoactive sexual desire disorder.
Design
Two randomised, double-blind, placebo-controlled phase 3 trials; 1,267 randomised.
Co-primary endpoints
Change in desire and distress scores. Satisfying sexual-event count was a separate endpoint.
A result in this population does not establish efficacy for men, postmenopausal women or people without the studied disorder. Questionnaire changes and event counts are different outcomes.
What the pivotal trials measured
The two RECONNECT phase 3 trials randomised 1,267 women; the modified intention-to-treat efficacy population contained 1,202. Over 24 weeks, bremelanotide improved desire scores and reduced distress associated with low desire compared with placebo. These were validated questionnaire endpoints. The prespecified absolute number of satisfying sexual events did not differ significantly between groups. [1]
This distinction matters: improvement in desire or distress is not identical to an increase in sexual activity. The predominantly white, US-based population also limits how confidently the same result can be assumed in every demographic or clinical setting. [1]
Longer follow-up and subgroup findings
The optional extension enrolled 684 participants, of whom 272 completed it. Symptoms remained improved among participants followed, but the study was open label and selected people who had completed the preceding phase. Attrition and selection can make long-term outcomes appear more favourable than they would in everyone initially treated. [2]
A subsequent analysis examined results across age, weight, body-mass index and other prespecified subgroups. Findings were broadly consistent, but these analyses reuse the RECONNECT participants; they should not be counted as a new independent trial. Nor do they expand the approved indication automatically. [3]
Human research and approved medical context
The US Vyleesi label describes subcutaneous bremelanotide for premenopausal women with acquired, generalised HSDD that is not attributable to another condition, relationship problems or a medication. It is not indicated to enhance sexual performance, or for men or postmenopausal women. This describes a US prescription product; it does not establish Australian registration or approval of Leni’s listing. [5]
Earlier intranasal research in healthy men and men with erectile dysfunction found pharmacodynamic responses, but it studied a different route and clinical objective. Those findings are historical research context, not instructions for converting or administering a vial. [4]
Safety and interpretation
The prescription label includes transient blood-pressure increases, heart-rate reduction, nausea and focal hyperpigmentation. Uncontrolled hypertension or known cardiovascular disease are contraindications. It also addresses effects on absorption of oral medicines and an interaction with oral naltrexone. [5]
In the extension study, nausea, flushing and headache remained common; the apparent absence of a broad new safety signal must be read alongside the limited completion rate. [2] An evidence-led synopsis can recognise the clinical benefits demonstrated for the defined population while keeping product equivalence, tolerability and eligibility separate. The listed research vial has not been shown by these studies to reproduce the prescription medicine’s quality or performance.
02 / Key studies
The evidence in detail.
| Study & design | Finding | How to read it |
|---|---|---|
| RECONNECT · 2019Two phase 3 RCTs · 1,267 randomised | Improved desire and related distress versus placebo. [1] | No significant change in the absolute satisfying-event endpoint. |
| RECONNECT extension · 2019Open label · 684 enrolled; 272 completed | Sustained questionnaire improvements among those followed. [2] | Selection bias, attrition and no concurrent placebo comparison. |
| Subgroup analysis · 2022Secondary analysis · n=1,202 | Broadly consistent findings across several subgroups. [3] | Reuses the pivotal trial dataset. |
| Intranasal PT-141 · 2004Early human pharmacology | Erectile response examined in male participants. [4] | Different formulation, route and indication. |
03 / Open questions
What is not established.
- US prescription approval is formulation- and indication-specific.
- The pivotal studies do not establish use in every sex, age group or cause of low desire.
- The research listing is not demonstrated to be equivalent to Vyleesi.
04 / Papers & sources
Go to the source.
Read the original papers below. Open-access full text is linked where available; publisher access may require a subscription. These summaries do not reproduce the papers.
-
01
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Reviewed: PubMed abstract and open-access full text: study design, efficacy, secondary endpoints and limitations.
-
02
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Reviewed: PubMed abstract + selected full-text results/discussion/limitations.
-
03
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Reviewed: PubMed abstract.
-
04
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.
Reviewed: PubMed abstract.
-
05
Vyleesi (bremelanotide): US prescribing information
Reviewed: Official prescribing information: clinical studies Tables 2 and 3, endpoint definitions, evaluable populations and adverse reactions.
How this page was researched
This is a targeted narrative review, not a systematic review or meta-analysis. Searches used compound names and aliases with terms for clinical trials, mechanisms, safety and specific research outcomes. Primary papers, PubMed records, selected open-access full-text sections, trial registries and official product or regulator documents were prioritised. Each source records what was inspected. Negative, mixed and small-study findings are retained. No claim is made that every publication has been captured.
Findings apply to the intervention and population studied. Evidence for a related molecule, another route or an approved medicine does not validate the Leni listing. The page has not been independently clinically or legally reviewed.
Related product listings and multipacks (4)
Multipacks change the item count, not the research evidence. Product-page names and specifications were captured from the live catalogue on 11 October 2026.